GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)

GILD Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0000882095 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$178.21B
1,239,955,155 shares Covers every share class this company has on file.
Insiders on file
16
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$191.56M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.11%
insider-held value divided by market capitalisation

What GILEAD SCIENCES, INC. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$29.44B
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$8.51B
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
17,000
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at GILEAD SCIENCES, INC.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against GILEAD SCIENCES, INC..
Insider Reported role Shares Value Last action
Officers 2
Andrew D Dickinson CFO 179,191 $27.06M F Shares withheld for taxes Sep 10, 2026 position reported
Sandra Patterson SVP 39,453 $5.96M — position reported
Officers who also sit on the board 7
Daniel Patrick O'Day CEO 642,567 $97.03M F Shares withheld for taxes Sep 10, 2026 position reported
Johanna Mercier Other Executive 131,779 $19.90M F Shares withheld for taxes Sep 10, 2026 position reported
Merdad Parsey Other Executive 82,850 $12.51M — position reported
Diane E Wilfong Chief Accounting Officer 46,259 $6.99M M Option exercise or conversion Sep 10, 2025 position reported
Deborah H Telman General Counsel 43,676 $6.60M M Option exercise or conversion Nov 12, 2025 position reported
Dietmar Berger Other Executive 18,982 $2.87M F Shares withheld for taxes Sep 10, 2026 position reported
Javier Rodriguez CEO 12,218 $1.84M A Grant or award Apr 30, 2026 position reported
Directors 7
Jacqueline K. Barton Board Member 26,056 $3.93M A Grant or award Apr 30, 2026 position reported
Harish Manwani Harish Manwani Board Member 14,093 $2.13M F Shares withheld for taxes Apr 30, 2026 position reported
Anthony Welters Board Member 11,748 $1.77M S Open-market sale Aug 26, 2026 position reported
Jeffrey Bluestone Board Member 8,920 $1.35M S Open-market sale Aug 20, 2026 position reported
Sandra Horning Sandra Horning Board Member 5,147 $777.2K A Grant or award Apr 30, 2026 position reported
Ted W. Love Board Member 4,338 $655.0K A Grant or award Apr 30, 2026 position reported
Kelly A Kramer Kelly A Kramer Board Member 1,339 $202.2K M Option exercise or conversion Nov 28, 2025 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Daniel Patrick O'Day sold 115,640 GILEAD SCIENCES, INC. (GILD) shares for $17,346,000 on Feb 5, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Daniel Patrick O'Day sold 115,640 GILEAD SCIENCES, INC. (GILD) shares for $17,346,000 on Feb 5, 2026
Date Insider Transaction Shares Price Value Filing
Feb 5, 2026 Daniel Patrick O'Day S Open-market sale 115,640 held after: 613,912 $150.00 $17,346,000 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Daniel Patrick O'Day sold 115,640 GILEAD SCIENCES, INC. (GILD) shares for $15,611,400 on Jan 23, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Daniel Patrick O'Day sold 115,640 GILEAD SCIENCES, INC. (GILD) shares for $15,611,400 on Jan 23, 2026
Date Insider Transaction Shares Price Value Filing
Jan 23, 2026 Daniel Patrick O'Day S Open-market sale 115,640 held after: 566,698 $135.00 $15,611,400 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Merdad Parsey sold 145,413 GILEAD SCIENCES, INC. (GILD) shares for $13,365,964 on Nov 27, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Merdad Parsey sold 145,413 GILEAD SCIENCES, INC. (GILD) shares for $13,365,964 on Nov 27, 2024
Date Insider Transaction Shares Price Value Filing
Nov 27, 2024 Merdad Parsey S Open-market sale 57,294 held after: 187,718 $91.79 $5,259,016 SEC filing ↗
Nov 27, 2024 Merdad Parsey S Open-market sale 88,119 held after: 99,599 $92.00 $8,106,948 SEC filing ↗

Total of the rows above: $13,365,964, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 335 rows we hold, 0 are open-market purchases and 126 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for GILEAD SCIENCES, INC., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 10, 2026 Johanna Mercier F Shares withheld for taxes 1,347 $144.81 $195.1K SEC filing ↗
Sep 10, 2026 Johanna Mercier M Option exercise or conversion 2,797 $0.00 $0 SEC filing ↗
Sep 10, 2026 Dietmar Berger F Shares withheld for taxes 263 $144.81 $38.1K SEC filing ↗
Sep 10, 2026 Dietmar Berger M Option exercise or conversion 533 $0.00 $0 SEC filing ↗
Sep 10, 2026 Daniel Patrick O'Day F Shares withheld for taxes 4,230 $144.81 $612.5K SEC filing ↗
Sep 10, 2026 Daniel Patrick O'Day M Option exercise or conversion 8,780 $0.00 $0 SEC filing ↗
Sep 10, 2026 Andrew D Dickinson F Shares withheld for taxes 1,347 $144.81 $195.1K SEC filing ↗
Sep 10, 2026 Andrew D Dickinson M Option exercise or conversion 2,797 $0.00 $0 SEC filing ↗
Sep 1, 2026 Daniel Patrick O'Day S Open-market sale 5,408 $149.38 $807.8K SEC filing ↗
Sep 1, 2026 Daniel Patrick O'Day S Open-market sale 7,992 $148.36 $1.19M SEC filing ↗
Sep 1, 2026 Daniel Patrick O'Day S Open-market sale 1,600 $147.51 $236.0K SEC filing ↗
Aug 26, 2026 Anthony Welters S Open-market sale 6,880 $148.82 $1.02M SEC filing ↗
Aug 26, 2026 Anthony Welters S Open-market sale 3,402 $148.24 $504.3K SEC filing ↗
Aug 26, 2026 Anthony Welters M Option exercise or conversion 10,282 $61.35 $630.8K SEC filing ↗
Aug 26, 2026 Anthony Welters S Open-market sale 4,600 $148.82 $684.6K SEC filing ↗
Aug 26, 2026 Anthony Welters S Open-market sale 3,118 $148.31 $462.4K SEC filing ↗
Aug 26, 2026 Anthony Welters M Option exercise or conversion 7,718 $60.67 $468.3K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone S Open-market sale 335 $146.26 $49.0K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone M Option exercise or conversion 335 $61.35 $20.6K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone S Open-market sale 26 $146.36 $3.8K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone M Option exercise or conversion 26 $67.45 $1.8K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone S Open-market sale 1,658 $145.73 $241.6K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone M Option exercise or conversion 1,658 $67.45 $111.8K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone S Open-market sale 1,816 $144.92 $263.2K SEC filing ↗
Aug 20, 2026 Jeffrey Bluestone M Option exercise or conversion 1,816 $67.45 $122.5K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — what this company owns

Corporate ownership links for GILEAD SCIENCES, INC.

What GILEAD SCIENCES, INC. owns

This company files as an owner of the companies below.

A name in plain text is the end of the trail: we hold the filing that names it, but no separate record to open.

GILEAD SCIENCES, INC.
Being named on an ownership form is not the same as legal parent–subsidiary control.

That relationship only holds if the filing says so. The map draws at most eight holdings per level, stops after two levels, and never doubles back on a name it has already passed through.

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 85 legal entities

Subsidiaries of GILEAD SCIENCES, INC.

85 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries GILEAD SCIENCES, INC. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
(as of December 31, 2025) —
Asegua Therapeutics LLC United States
Calla Holdings, LLC United States
Calla Merger Sub, Inc. United States
CymaBay Canada, Ltd. Canada
CymaBay Ireland, Limited Ireland
CymaBay Therapeutics, Inc. United States
CymaBay UK, Ltd. United Kingdom
Cytopia Pty. Ltd. Australia
Forty Seven Holdings, LLC United States
Forty Seven, LLC United States
Gilead Alberta ULC Canada
Gilead Alberta, LLC United States
Gilead Apollo Unlimited Company Ireland
Gilead Apollo, LLC United States
Gilead Biopharmaceutics Ireland UC Ireland
Gilead Biopharmaceutics US LLC United States
Gilead Calistoga, LLC United States
Gilead Connecticut, Inc. United States
Gilead Holdings, LLC United States
Gilead Pharmasset LLC United States
Gilead Sciences (GSR) S.R.L. Romania
Gilead Sciences (NZ) New Zealand
Gilead Sciences (Shanghai) Consulting Co., Ltd. China
Gilead Sciences Americas S. de R.L. Panama
Gilead Sciences Arabia Limited Company Saudi Arabia
Gilead Sciences Argentina S.R.L. Argentina
Gilead Sciences Belgium BV Belgium
Gilead Sciences Canada, Inc. Canada
Gilead Sciences Colombia S.A.S. Colombia
Gilead Sciences Denmark ApS Denmark
Gilead Sciences Europe Limited United Kingdom
Gilead Sciences Farmacêutica do Brasil Ltda. Brazil
Gilead Sciences Finland Oy Finland
Gilead Sciences GesmbH Austria
Gilead Sciences GmbH Germany
Gilead Sciences Hangzhou Pharmaceutical Co., Ltd. China
Gilead Sciences Hellas EPE Greece
Gilead Sciences Holding, LLC United States
Gilead Sciences Hong Kong Limited Hong Kong
Gilead Sciences Ilac Ticaret Limited Sirketi Turkey
Gilead Sciences India Private Limited India
Gilead Sciences International Limited United Kingdom
Gilead Sciences Ireland Unlimited Company Ireland
Gilead Sciences Israel Limited Israel
Gilead Sciences KK Japan
Gilead Sciences Korea Limited South Korea
Gilead Sciences Limited United Kingdom
Gilead Sciences Luxembourg S.a.r.l. Luxembourg
Gilead Sciences Malaysia Sdn. Bhd. Malaysia
Gilead Sciences Mexico S. de R.L. de C.V. Mexico
Gilead Sciences Netherlands B.V. Netherlands
Gilead Sciences Norway AS Norway
Gilead Sciences Poland Sp. z.o.o. Poland
Gilead Sciences Pty. Ltd. Australia
Gilead Sciences Russia LLC Russia
Gilead Sciences S.L.U. Spain
Gilead Sciences S.r.l. Italy
Gilead Sciences s.r.o. Czech Republic
Gilead Sciences SAS France
Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd. China
Gilead Sciences Singapore Pte. Ltd. Singapore
Gilead Sciences Slovakia s.r.o. Slovakia
Gilead Sciences South Africa (Pty) Ltd. South Africa
Gilead Sciences Sweden AB Sweden
Gilead Sciences Switzerland Sarl Switzerland
Gilead Sciences YM Australia Pty. Ltd. Australia
Gilead Sciences, Lda. Portugal
Gilead Sciences, LLC United States
Gilead Therapeutics A1 Unlimited Company Ireland
Gilead YM ULC Canada
IBC Pharmaceuticals, Inc. United States
Immunomedics GmbH Germany
Immunomedics, Inc. United States
Interius Biotherapeutics, Inc. United States
Kite Pharma EU B.V. Netherlands
Kite Pharma, Inc. United States
Kite Pharma, LLC United States
KP EU C.V. Netherlands
MiroBio Ltd. United Kingdom
MYR GmbH Germany
neoKite, Inc. United States
Tmunity Therapeutics, Inc. United States
XinThera, Inc. United States
YM BioSciences Australia Pty. Ltd. Australia
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from GILEAD SCIENCES, INC.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from GILEAD SCIENCES, INC.’s own SEC filings multiplied by the closing price we hold for the same stock.